Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis

International Journal of Rheumatic Diseases

Volumn 12, Issue 1, 2009, Pages 7-13

  Suzuki, Yutaka ^a   Inoue, Kazuhiko ^a   Chiba, Junji ^a   Inoue, Yasuo ^a   Kanbe, Katsuaki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Etanercept; Histology; IL 6; Rheumatoid arthritis; Synovium; TNF

Indexed keywords

BROXURIDINE; CD20 ANTIGEN; CD68 ANTIGEN; EOSIN; ETANERCEPT; HEMATOXYLIN; INTERLEUKIN 6; MEMBRANE PROTEIN; METHOTREXATE; PREDNISOLONE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTHROSCOPY; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVECTOMY; SYNOVIUM;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 3; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63849087730     PISSN: 17561841     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2009.01372.x     Document Type: Article

References (19)

1. Harris ED Jr (1990) Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 322, 1277-89.
2. Nishimoto N (2006) Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 18, 277-81.
3. Elliott MJ, Maini RN, Fledmann M, et al. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36, 1681-90.
4. Nakahara H, Song J, Sugimoto M, et al. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48, 1521-9.
5. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54, 1063-74.
6. Lindberg J, af Klint E, Catrina AI, et al. (2006) Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 8, R179.
7. Breedveld FC, Weisman MH, Kavanaugh AF, et al. (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54, 26-37.
8. Smolen JS, Maini RN (2006) Interleukin-6: A new therapeutic target. Arthritis Res Ther 8, 407.
9. Cohen SB, Emery P, Greenwald MW, et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54, 2793-806.
10. Kremer JM, Dougas M, Emery P, et al. (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase II, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52, 2263-71.
11. Steinbrocker O, Traeger CH, Battman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140: 659-62.
12. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-24.
13. Van der Heijde DM, van't Hof MA, van Riel PL, et al. (1990) Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Ann Rheum Dis 49, 916-20.
14. Farahat MN, Yanni G, Poston R, Panayi GS (1993) Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rhem Dis 52, 870-5.
15. Zink A, listing J, Kary S, et al. (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64, 1274-9.
16. Takemura T, Kanbe K, Takeuchi K, Inoue K, Takagishi K (2005) Serum matrix metalloproteinase activity relating to cartilage destruction in rheumatoid arthritis. APLAR J Rheumatol 8, 213-9.
17. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC (2000) Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 43, 2391-6.
18. Kanbe K, Inoue K (2006) Efficacy of arthroscopic synovectomy for the effect attenuation cases of infliximab in rheumatoid arthritis. Clin Rheumatol 25, 877-81.
19. Takemura T, Kanbe K, Takeuchi K, Inoue K, Takagishi K (2005) Serum matrix metalloproteinase activity relating to cartilage destruction in rheumatoid arthritis. APLAR J Rheumatol 8, 213-9.